FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.

Original reporting
Published Nov 17, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$NVS
Bullish
medium confidence
Mentioned
$NVS
Relevance
7/10
AlphAI data visualization · based on medscape.com
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The approval is supported by Phase 3 REPLENISH results showing nearly doubled sustained remission rates versus placebo and no new safety signals, positioning secukinumab as a steroid-sparing option in PMR.

02

Market read

Traders can treat this as a fresh regulatory catalyst for Novartis’ Cosentyx franchise, with potential incremental demand from a new PMR label and a near-term sentiment tailwind.

03

What to watch

Real-world uptake will depend on payer coverage, clinician comfort with IL-17 in PMR, and how quickly EU approval and guideline updates translate into prescribing behavior.

Relevance 7/10Novelty 9/10Timing: FDA approval reported today, with immediate implications for Cosentyx/Novartis sentiment.

Background

Secukinumab (Cosentyx) is an anti-IL-17A monoclonal antibody already approved for multiple inflammatory diseases; this FDA decision adds PMR for adults with inadequate response to corticosteroids or inability to taper.

Company-level read

Ticker impact

$NVSBullishMedium confidence
Context

FDA approval of Novartis' secukinumab (Cosentyx) for polymyalgia rheumatica expands the drug’s labeled indications beyond existing autoimmune uses.

Expected impact

Likely positive bias as investors price in expanded addressable market and potential uptake from steroid-inadequate or intolerant PMR patients.

Evidence & confidence

The article is a direct FDA regulatory approval tied to Novartis’ product, with supportive Phase 3 REPLENISH efficacy and no new safety signals reported.

Market effects

Reinforces IL-17 pathway competitiveness in inflammatory rheumatology and may shift treatment expectations toward steroid-sparing biologics.

US label expansion is immediate; EU marketing authorization is expected soon, potentially extending the catalyst window.

Could accelerate global adoption discussions for PMR management guidelines where biologics are considered after steroid failure or intolerance.

Counterpoint

PMR is a niche indication relative to Cosentyx’s broader psoriasis/psoriatic arthritis footprint, so near-term financial impact may be modest versus market expectations.

Key entities

  • Novartis

    Manufacturer of secukinumab (Cosentyx), whose product received FDA approval for polymyalgia rheumatica.

  • secukinumab (Cosentyx)

    Anti-IL-17A monoclonal antibody approved for PMR in adults with inadequate steroid response or steroid intolerance.

  • REPLENISH trial

    Phase 3 program evaluating secukinumab plus a prednisone taper in adults with PMR.

  • European Commission

    Expected to issue a final EU decision soon after EMA’s positive recommendation.

Related articles

$NVSMed

FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

$NVSMed

Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

$NVSMed

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

$NVSMed

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.